Sandia Investment Management LP Hille Vax, Inc. Transaction History

Sandia Investment Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$13.52 - $21.46 $25,688 - $40,774	-1,900 Reduced 24.05%	6,000 $100,000
Q3 2022 Nov 14, 2022	SELL	$10.5 - $22.01 $48,300 - $101,246	-4,600 Reduced 36.8%	7,900 $135,000
Q2 2022 Aug 15, 2022	BUY	$8.7 - $20.18 $108,749 - $252,250	12,500 New	12,500 $137,000

36.8M

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $66.9M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Get notified when there are updates to the investment portfolio of Sandia Investment Management LP, based on Form 13F filings with the SEC.

Stay updated on Sandia Investment Management LP with notifications on news.